Trials / Unknown
UnknownNCT02908958
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Children Growth Hormone Deficiency: A Multicenter, Randomized, Parallel, Dose-control Clinical Trial II
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 900 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of PEG Somatropin Injection (Jintrolong®) in the treatment of short stature due to endogenous growth hormone deficiency (GHD) in the broad of population of children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PEG-somatropin | High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks. |
| BIOLOGICAL | PEG-somatropin | Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks. |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2017-06-01
- First posted
- 2016-09-21
- Last updated
- 2017-06-14
Locations
22 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02908958. Inclusion in this directory is not an endorsement.